This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Over the past decade, macro trends in healthcare have pushed life sciences companies to pursue increasingly sophisticated keyaccountmanagement (KAM) strategies and capabilities to provide unique offerings and value. As a consequence, pharma companies will need to rethink team sizing and resource allocation to accounts.
It’s important to: Consider looking at other roles that are not direct sales positions such as keyaccountmanagers, reimbursement specialists, and contact center support teams. reimbursement managers) to support the HCPs and their patients. Create added value by appropriately introducing services (e.g.
According to the GlobalData report Contract Injectable Packaging Trends in the Bio/Pharma Industry , more than half (55%) of FDA drug approvals in 2021 were accounted for by injectables. This was higher than the number of approvals in 2019 and 2020. Several drug development trends are driving injectables demand.
“The CROs were key in maintaining the communication and the need for logistics as well,” says Mark Woolf, chief business development officer for Oximio. In a period of just over a year before the war started, between 26 October 2020 and 1 January 2022, Ukraine had 255 clinical trials either running or completed. Credit: Oximio.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content